Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia

Muhammad Rizwan Khawaja, Susan M. Perkins, Jennifer E. Schwartz, Michael J. Robertson, Patrick J. Kiel, Hamid Sayar, Elizabeth A. Cox, Gail H. Vance, Sherif S. Farag, Larry D. Cripe, Robert P. Nelson

Research output: Contribution to journalArticle

Abstract

We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have secondary AML and lower performance status. At a median follow-up of 61 months, median event-free survival and overall survival survival were not different between NMAT and MAT in univariate as well as multivariate analyses. Cy/Flu NMAT may provide similar disease control and survival when compared with MAT in patients with AML in remission or without frank relapse. Am. J. Hematol. 90:97-99, 2015.

Original languageEnglish (US)
Pages (from-to)97-99
Number of pages3
JournalAmerican Journal of Hematology
Volume90
Issue number2
DOIs
StatePublished - Feb 1 2015

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Khawaja, M. R., Perkins, S. M., Schwartz, J. E., Robertson, M. J., Kiel, P. J., Sayar, H., Cox, E. A., Vance, G. H., Farag, S. S., Cripe, L. D., & Nelson, R. P. (2015). Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia. American Journal of Hematology, 90(2), 97-99. https://doi.org/10.1002/ajh.23875